Multiple RSV vaccines in late-stage development show promise in older adults
October 20, 2022 (WASHINGTON) — Three late-breaking studies offered a promising glimpse of respiratory syncytial virus vaccines in the pipeline for older adults — including the RSVPreF3 OA vaccine, which showed an overall vaccine efficacy of about 83%.
The latest results from the RSVPreF3 OA vaccine were initially announced by GlaxoSmithKline (GSK) in a press release last week. The vaccine contains a recombinant subunit pre-fusion RSV antigen, combined with an adjuvant called AS01E.